The impact of early molecular response in children and adolescents with chronic myeloid leukemia treated with imatinib: a single-center study from China.

about

The impact of early molecular response in children and adolescents with chronic myeloid leukemia treated with imatinib: a single-center study from China.

Item

http://www.wikidata.org/entity/Q48243531

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

The impact of early molecular ...... ingle-center study from China.

@en

The impact of early molecular ...... ingle-center study from China.

@nl

type

Item

label

The impact of early molecular ...... ingle-center study from China.

@en

The impact of early molecular ...... ingle-center study from China.

@nl

prefLabel

The impact of early molecular ...... ingle-center study from China.

@en

The impact of early molecular ...... ingle-center study from China.

@nl

P1476

The impact of early molecular ...... ingle-center study from China.

@en

P2093

Chunxiao Wu

http://www.w3.org/2001/XMLSchema#string

Haigang Shao

http://www.w3.org/2001/XMLSchema#string

Huiying Qiu

http://www.w3.org/2001/XMLSchema#string

Jiannong Cen

http://www.w3.org/2001/XMLSchema#string

Jun Zhang

http://www.w3.org/2001/XMLSchema#string

Shuxiao Bai

http://www.w3.org/2001/XMLSchema#string

Suning Chen

http://www.w3.org/2001/XMLSchema#string

Yanlei Gong

http://www.w3.org/2001/XMLSchema#string

Yong Wang

http://www.w3.org/2001/XMLSchema#string

Zhao Zeng

http://www.w3.org/2001/XMLSchema#string

P2860

Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION).

Chronic myeloid leukaemia.

Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)

How I treat childhood CML.

Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results.

Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities

Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV.

Harmonization of molecular monitoring of CML therapy in Europe.

P304

2152-2158

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/10428194.2017.1422860

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Jinlan Pan

P577

2018-01-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29334300

http://www.w3.org/2001/XMLSchema#string

P921

chronic myeloid leukemia